Could Patent Reform Hurt Cleantech?

In Sapphire Energy’s case it started with asking a set of fundamental questions, “Can we make a carbon-neutral fuel domestically, using no agricultural land and non-potable water, that is compatible with the existing distribution and refining infrastructure, at $60 a barrel, at a scale of 1 million barrels per day.”

Without significant venture capital investment of $100,000 to $150 million, these promising technologies that underpin the future of our country and our world will not be developed. Only after these seed and early stage investments have demonstrated the viability of an idea can they attract even larger corporate partner commitments, which can range from $200 million to billions of dollars.

The reality of cleantech today is that small companies must negotiate with large companies for capital to survive, especially in constrained financial markets. In order to get the corporate deals, the negotiations rest solely on the proprietary strength of the patent applications and patents. Substantial changes in the way we approach damages in these pioneering cases, are likely to inadvertently but fundamentally change the business dynamic. Essentially, it will increase the original business risk so that the first investment does not take place. In addition, large companies may take advantage of the increased power that apportionment of damages gives them, even if apportionment was meant to solve an entirely different problem. They may wait to invest, and these technologies may never get to scale and ultimately benefit the public.

The type of seed venture capital and pioneering work we do is already a tentative business, and small perturbations in the system can have large effect in investment, innovation, and U.S. competitive advantage. Successful economic development of important new ideas requires a constructive partnership relationship between the small, nimble, wildcatter venture-based start-ups and the large, capital-rich corporate partners, which move more slowly if at all. Like many effects of policy, the business reality will take effect immediately in the game theory of the negotiation, 10 years before the first litigation and damages. In the meantime, the uncertainty and tilt toward lower innovation and entrenched market leaders, will serve to quash the breakthrough innovations and solutions we need to solve the pressing problems we face.

We must ensure that cleantech innovation is enhanced, not suppressed, by patent reform and that all sides are heard so we craft the best possible legislation to solve the problems of the tech industry while not harming cleantech.

We must address the problems that the technology industry has raised. It is unacceptable that patenting the font for the letter “O” should stop an operating system. We should make sure that the patenting of immaterial inventions does not hurt our technology companies. Yet we should make sure to solve the problems they face, and not risk inflicting collateral damage on the worker bees of our economy. The creation of a “gate keeping” standard, which lets the court apportion damages when there is an apparently frivolous case, solves the very problem that has been raised without creating a huge new risk.

Apportionment of damages without some standard of materiality could be devastating to clean-tech and other innovations. The inadvertent harm to the most competitive and important industries we are creating could be real and fast, ceding strength to foreign competitors.

In United States history there has always been the inclination to support the individual, to protect the weak from the strong, to make the assumption that someone who has a new idea should be heard. I urge the Committee to consider this history and think of the real example of carbon neutral oil – a case that is playing out as we speak. Your actions on patent reform and damages will have real effects on the survival of cleantech and other innovative industries in their tentative relationships with the goliaths of the energy world this year and next, well before the first case is decided. We all have a stake in that outcome.

Author: Robert Nelsen

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He focuses on biotechnology, pharmaceuticals, and nanotechnology. Mr. Nelsen joined ARCH at its founding and has played a significant role in the early sourcing, financing and development of more than thirty companies including Ikaria, Adolor (ADLR), Aviron (AVIR, acquired by Medimmune-MEDI), Caliper Life Sciences (CALP), Illumina (ILMN), Trubion Pharmaceuticals (TRBN), Array BioPharma (ARRY), NetBot, deCODE Genetics (DCGN), Nanosys, Alnylam Pharmaceuticals (ALNY), XenoPort (XNPT), GenVec (GNVC), R2 Technology (acquired by Hologic-HOLX), IDUN Pharmaceuticals (acquired by Pfizer-PFE), Genomica (GNOM, acquired by Exelixis-EXEL), Surface Logix, NeurogesX (NGSX), Classmates.com (acquired by United Online-UNTD), Nura (acquired by Omeros), Kythera Biopharmaceuticals, Elixir Pharmaceuticals, Spaltudaq, VLST, Ensemble Discovery, Accelerator, Apoptos, Fate Therapeutics, Agios Therapeutics, and Everyday Learning. Mr. Nelsen is a director of Sapphire Energy, Ikaria, Agios, NeurogesX, and Kythera Biopharmaceuticals. He previously served on the boards of Trubion Pharmaceuticals, Surface Logix, NetBot, Everyday Learning, Spaltudaq, Array BioPharma, Caliper Life Sciences, Illumina, R2 Technology, and Classmates.com, among others. He also serves as a director of the Fred Hutchinson Cancer Research Center. Mr. Nelsen holds an M.B.A. from The University of Chicago and a B.S. in Economics and Biology from the University of Puget Sound.